Apolipoproteins: New players in cancers

Yingcheng He; Jianrui Chen; Yanbing Ma; Hongping Chen

doi:10.3389/fphar.2022.1051280

Apolipoproteins: New players in cancers

Front Pharmacol. 2022 Nov 25:13:1051280. doi: 10.3389/fphar.2022.1051280. eCollection 2022.

Authors

Yingcheng He^{1

2}, Jianrui Chen^{1

2}, Yanbing Ma^{1

2}, Hongping Chen^{1

3}

Affiliations

¹ Department of Histology and Embryology, Medical College of Nanchang University, Nanchang, Jiangxi, China.
² Medical Department, Queen Mary School, Nanchang University, Nanchang, Jiangxi, China.
³ Jiangxi Key Laboratory of Experimental Animals, Nanchang University, Nanchang, Jiangxi, China.

Abstract

Apolipoproteins (APOs), the primary protein moiety of lipoproteins, are known for their crucial role in lipid traffic and metabolism. Despite extensive exploration of APOs in cardiovascular diseases, their roles in cancers did not attract enough attention. Recently, research focusing on the roles of APOs in cancers has flourished. Multiple studies demonstrate the interaction of APOs with classical pathways of tumorigenesis. Besides, the dysregulation of APOs may indicate cancer occurrence and progression, thus serving as potential biomarkers for cancer patients. Herein, we summarize the mechanisms of APOs involved in the development of various cancers, their applications as cancer biomarkers and their genetic polymorphism associated with cancer risk. Additionally, we also discuss the potential anti-cancer therapies by virtue of APOs. The comprehensive review of APOs in cancers may advance the understanding of the roles of APOs in cancers and their potential mechanisms. We hope that it will provide novel clues and new therapeutic strategies for cancers.

Keywords: anti-cancer therapy; apolipoproteins; cancer biomarker; cancer mechanism; genetic polymorphism.

Publication types

Review